Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World dupilumab study aims to improve COPD Patients' daily lives

NCT ID NCT07052396

Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 350 adults with uncontrolled COPD who are starting dupilumab, a medication that reduces lung inflammation. Researchers will track changes in quality of life and breathing symptoms over two years using simple questionnaires. The goal is to see how well the drug works outside of a controlled clinical setting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 350 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jul 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will be screened, enrolled, and documented by their treating physician. To avoid any selection bias, all eligible participants will be invited to participate in this study in the order in which their eligibility is determined (consecutive recruitment). Participants will be treated within clinical routine practice and according to the current standard of care. Participants who permanently discontinue dupilumab treatment and therefore terminate the study prior to the last visit at month 24 will be requested to complete an Early Termination visit.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants willing and able to sign informed consent for use of their pseudonymized clinical data within the present non-intervention study. * Adult participants. * Participants with uncontrolled Chronic Obstructive Pulmonary Disease (COPD) despite long-acting muscarinic antagonist (LAMA)/ long-acting beta2-agonist (LABA)/ Inhaled Corticosteroid (ICS) (or LAMA/LABA if ICS are not appropriate) therapy and elevated blood eosinophils * Participants newly initiated on dupilumab treatment as indicated in the dupilumab Summary of Product Characteristics (SmPC) in the specified label for COPD, determined by the treating physician, and independent of participation in the non-interventional study (NIS). Exclusion Criteria: * Participants not eligible for dupilumab treatment according to SmPC. * Participation in an ongoing interventional or observational study or participation in an interventional or observational study up to 12 months before enrolment that might, in the treating physician's opinion, influence the assessments for the current study. * Any acute or chronic condition that, in the treating physician´s opinion, would limit the participants´s ability to complete questionnaires or to participate in this study or impact the interpretation of the results. * Participants hospitalized due to an exacerbation of their COPD within the last 4 weeks prior to enrolment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease (COPD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic obstructive pulmonary disease (COPD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    18 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Investigational Site Number: DE01

    RECRUITING

    Darmstadt, 64283, Germany

  • Investigational Site Number: DE02

    RECRUITING

    Berlin, 14163, Germany

  • Investigational Site Number: DE03

    RECRUITING

    Hamburg, 20354, Germany

  • Investigational Site Number: DE04

    RECRUITING

    Hamburg, 22459, Germany

  • Investigational Site Number: DE06

    RECRUITING

    Flensburg, 24937, Germany

  • Investigational Site Number: DE07

    RECRUITING

    Hohenstein-Ernstthal, 09337, Germany

  • Investigational Site Number: DE08

    RECRUITING

    Fürstenwalde, 15517, Germany

  • Investigational Site Number: DE09

    RECRUITING

    Erkelenz, 41812, Germany

  • Investigational Site Number: DE10

    RECRUITING

    Itzehoe, 25524, Germany

  • Investigational Site Number: DE13

    RECRUITING

    Bad Homburg, 61350, Germany

  • Investigational Site Number: DE14

    RECRUITING

    Markkleeberg, 04416, Germany

  • Investigational Site Number: DE18

    RECRUITING

    Auerbach, 08209, Germany

  • Investigational Site Number: DE19

    RECRUITING

    Berlin, 10717, Germany

  • Investigational Site Number: DE20

    RECRUITING

    Marburg, 35037, Germany

  • Investigational Site Number: DE21

    RECRUITING

    Augsburg, 86152, Germany

  • Investigational Site Number: DE24

    RECRUITING

    Kaiserslauten, 67655, Germany

  • Investigational Site Number: DE25

    RECRUITING

    Lüneburg, 21339, Germany

  • Investigational Site Number: DE29

    RECRUITING

    Burgwedel, 30938, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.